Novo Nordisk's Lawsuits Against GLP-1 Compounders: What They Mean for Patients

Your provider’s legal status matters more than it ever has. If you are on compounded semaglutide in 2026, you are getting your medication from a company that is either in active litigation, has settled and exited the market, or is operating in the shadow of both FDA enforcement and manufacturer patent claims.

This article explains what Novo Nordisk’s February 2026 lawsuits actually say, who they named, what happened to Hims, and what the litigation means for patients who are still on compounded semaglutide from providers like Mochi Health and Fella Health.

What Novo Nordisk filed and why

On February 9, 2026, Novo Nordisk filed patent infringement lawsuits in the US District Court for the District of Delaware against Hims & Hers and 14 other firms selling compounded semaglutide products. Additional suits followed in subsequent weeks.

The central legal claim: all of these companies are infringing US Patent No. 8,129,343 — Novo Nordisk’s compound patent covering the semaglutide molecule itself.

The theory of infringement is straightforward. Novo argues that the patent covers semaglutide as a chemical compound, regardless of how it is formulated, who makes it, or under what regulatory framework it is dispensed. The complaint states that “all compounded versions of drugs containing semaglutide unlawfully incorporate the patented ingredient and circumvent the FDA’s new drug approval process.”

The timing was not coincidental. Hims had just announced on February 5, 2026 — four days before the suit was filed — a compounded oral semaglutide pill starting at $49 per month, undercutting Novo’s branded Wegovy pill at $149/month via LillyDirect. The announcement triggered the lawsuit.

The §503A problem: two separate bodies of law

This is the point most coverage of this litigation has missed, and the one patients need to understand.

The compounding providers targeted in this litigation have generally been operating under the §503A(b)(1)(D) personalised-need exemption — the FDA regulatory pathway that permits a licensed pharmacist to compound a drug for an identified patient when the prescriber documents a clinical justification for personalisation. All 503B outsourcing-facility authority for GLP-1 bulk substances lapsed on May 22, 2025. For a plain-language explanation of both pathways, see 503A vs 503B pharmacies explained.

The §503A pathway is an FDA regulatory matter. Novo Nordisk’s patent is a federal intellectual property matter. These are entirely separate.

A compounder can be in full compliance with the §503A framework — have a valid pharmacist’s licence, a legitimate patient-specific prescription, and proper clinical justification — and still be infringing US Patent No. 8,129,343 by using the patented semaglutide compound. FDA compliance does not confer patent immunity.

This is why the February 2026 suits represent a second legal threat layer, not simply a continuation of the enforcement pressure patients were already aware of. Providers that had adapted to the §503A landscape — survived the 503B deadline, continued operating under the personalised-need carve-out — are now facing patent litigation that the §503A framework cannot protect them from.

What happened to Hims: the settlement pattern

Hims & Hers settled with Novo Nordisk on March 9, 2026 — approximately one month after the lawsuit was filed.

The settlement terms were not disclosed publicly. The visible outcome: Hims exited its compounded semaglutide and oral semaglutide programs and became a NovoCare partner, selling brand-name Wegovy at manufacturer-direct pricing instead. Hims patients who were on compounded semaglutide were transitioned to the NovoCare program or given exit notice.

This settlement pattern — file suit, settle within weeks, the company pivots to branded — reflects the underlying economics. Hims calculated that the cost of defending the patent litigation plus the ongoing reputational and regulatory risk from compounding outweighed the revenue from the compounded program. The $49/month price point was not viable if it carried unlimited patent litigation exposure.

Patients in GLP-1 communities had already picked up on this dynamic before the settlement. The Costco/Wegovy pricing announcement triggered a common response: “Zero savings. This is already the price directly from the manufacturer. It is also still way overpriced and there are many other ways to get these medications for around $200 per month.” The frustration is legitimate — manufacturer-direct pricing at $349/month for Wegovy is not accessible to many patients, and the compounded path that made it accessible is now under patent pressure.

The active defendants: Mochi, Fella, and others

As of May 2026, Mochi Health and Fella Health are among the named defendants that have not settled with Novo Nordisk and are still in active litigation. Both continue operating their compounded semaglutide programs under §503A(b)(1)(D).

Fella Health: Novo Nordisk’s case against Fella proceeded to a denial of Fella’s motion to dismiss — meaning a federal judge allowed Novo’s patent claims to move forward. Eli Lilly has since cited the Fella ruling as precedent in its separate false-advertising case against Mochi Health, noting the similarity of the legal positions.

Mochi Health: Facing parallel litigation. The Eli Lilly case (Case 3:25-cv-03534-JSC, N.D. California) is the primary active litigation against Mochi, but Novo Nordisk’s patent claims add a second exposure. Lilly’s motion to dismiss was denied in April 2026. Mochi is contesting both.

Neither company has been ordered to stop operations. Court injunctions are separate from lawsuit filings, and courts have not issued injunctions against either provider as of May 2026. Active litigation means the risk of operational disruption is elevated — not that disruption is imminent.

Novo vs Lilly: two different legal theories

For patients tracking this, the distinction between Novo Nordisk’s suits and Eli Lilly’s suits matters:

Novo Nordisk (February 2026): Patent infringement. The claim is that using semaglutide in any compounded product infringes the compound patent. This applies to all compounded semaglutide regardless of what claims the provider makes about it.

Eli Lilly (filed April 2025, proceeding in 2026): Lanham Act false advertising + California UCL. The claim is that specific providers — Mochi, Henry Meds, and others — marketed compounded tirzepatide as equivalent to FDA-approved Zepbound after the shortage justification for compounding ended, deceiving consumers and diverting sales from Lilly.

These are different drugs, different theories, and different courts. But they create a pincer effect: Novo is pursuing compounded semaglutide providers on patent grounds; Lilly is pursuing compounded tirzepatide providers on false-advertising grounds. Together they represent both of the major compounded GLP-1 pathways facing legal pressure simultaneously.

What patients currently on compounded semaglutide should know

The litigation does not mean your current medication is unsafe — for an in-depth look at how compounded vs brand semaglutide compare, see that guide. It does mean your provider’s operational continuity is less certain than it was a year ago. Based on what happened with Hims, here are the practical implications:

Settlement can happen quickly. Hims went from lawsuit to settlement in 28 days. If Mochi Health or Fella Health settle in a similar pattern, patients may have limited notice before the compounded program winds down.

§503A compliance does not protect supply. If a provider loses a patent case or settles, their obligation to cease infringing — i.e., to stop selling compounded semaglutide — is separate from whether they were following FDA rules. Both can be true simultaneously.

Know your alternatives now. NovoCare ($349/month for Wegovy) and LillyDirect ($299–$449/month for Zepbound by dose tier) are the primary manufacturer-direct fallback options. If your commercial insurance covers Wegovy or Zepbound with a savings card, a prior-auth denial now may be worth re-appealing given the shifting compounded supply picture. See our prior authorization appeal guide for the step-by-step process.

The compounding tracker is your real-time source. We track provider legal status, FDA warning letters, and operational changes at /regulatory/compounding-tracker, updated weekly. If your provider’s status changes, it will be reflected there first.

The broader context: why this matters beyond this moment

The patent litigation is not the only legal pressure on compounders. There are three concurrent legal vectors:

1. FDA enforcement — All 503A and 503B enforcement-discretion windows for GLP-1 compounding expired May 22, 2025 (see the FDA compounding cliff for the full timeline). Providers remaining under §503A(b)(1)(D) are operating under the narrowest possible regulatory pathway.

2. Novo Nordisk patent claims — Compound patent covers semaglutide regardless of regulatory pathway; Hims settled, others in active litigation.

3. Eli Lilly false-advertising claims — Targeted at providers marketing compounded tirzepatide as equivalent to Zepbound after the shortage rationale ended.

None of these individually ended the compounding market. Together, they have substantially narrowed it. The providers still operating have calculated that the risk is manageable; that calculation can change with a court ruling, a settlement, or an FDA enforcement action.

This article summarises publicly filed court documents, company press releases, and regulatory guidance as of May 2026. It does not constitute legal advice. Provider operational status changes rapidly — see /regulatory/compounding-tracker for current status. Related: 503A vs 503B Pharmacies Explained · Hims Compounded Wind-Down · Switch From Compounded to Brand